Clinical Trials Browser

Recurrence × dacomitinib × Clear all

NCT01520870 2021-07-06

Safety and Efficacy of PF-299804 (Dacomitinib), a Pan-HER Irreversible Inhibitor, in Patients With Recurrent Glioblastoma With EGFR Amplification or Presence of EGFRvIII Mutation. A Phase II CT.

Phase 2 Completed

49 enrolled 9 charts

Brain Neoplasms, Glioblastoma, Recurrence

NCT04768491 2021-02-24

Dacomitinib Treatment Followed by 3rd Generation EGFR-TKI in Patients With EGFR Mutation Positive Advanced NSCLC

Carcinoma, Non-Small-Cell Lung, Recurrence

NCT00768664 2021-02-09

Open-Label Trial Of Oral PF-00299804 By Continuous Dosing In Patients With Recurrent Or Metastatic Head And Neck Squamous Cell Cancer

Phase 2 Completed

69 enrolled 18 charts

Head and Neck Neoplasms, Recurrence